InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Browse the full record of transactions filed by Ronsheim Matthew, Dirigeant. Officer active across 1 companies, notably Entasis Therapeutics Holdings Inc.. Cumulatively, 6 reports have been logged. The latest transaction was disclosed on 18 January 2022 (Attribution). Regulator: SEC (Form 4). All data is free.
Declarations6 total
0125,000 shares0
Common Stock
SEC:0001104659-22-005425·
0125,000 shares0
Common Stock
SEC:0001104659-22-005425:0·
€9,2993,669 shares@ €2.5346100.0% of flow
Common Stock
SEC:0001104659-21-133635·
€9,2993,669 shares@ €2.534650.0% of flow
Common Stock
SEC:0001104659-21-133635:0·
025,000 shares0
Common Stock
SEC:0001104659-21-128054·
025,000 shares0
Common Stock
SEC:0001104659-21-128054:0·
6 of 6 declarations
About Ronsheim Matthew
Matthew Ronsheim is Chief, Pharma Sciences & MFG. at Entasis Therapeutics Holdings Inc. He is responsible for pharmaceutical sciences and manufacturing within the company. His technical expertise is crucial for developing high-quality products.
